Showing results (491-500 of 624) with videos related to

Sort By:
Pageof 63
Leukemia|February 24, 2001
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995V Conter, M Aricò, M G Valsecchi, et al.
Lancet (London, England)|December 12, 1992
Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemiaF Lo Coco, D Diverio, P P Pandolfi, et al.
Cellular and Molecular Neurobiology|November 18, 2011
Epinephrine: a short- and long-term regulator of stress and development of illness : a potential new role for epinephrine in stressDona Lee Wong, T C Tai, David C Wong-Faull, et al.
British Journal of Haematology|October 16, 1999
Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow TransplantationD W Milligan, M C Ruiz De Elvira, H J Kolb, et al.
British Journal of Haematology|January 1, 1994
Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia PediatricaF Giona, A M Testi, L Annino, et al.
Cancer Research|July 15, 1997
Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemiasG Cimino, M C Rapanotti, A Biondi, et al.
Clinical Colorectal Cancer|December 3, 2014
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancerAndrea Cercek, Jinru Shia, Marc Gollub, et al.
International Journal of Oncology|November 16, 2012
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expressionSuqin He, Chaohua Zhang, Ayesha A Shafi, et al.
Leukemia & Lymphoma|October 1, 2016
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the bloodAmber Shatzer, Mir A Ali, Mayra Chavez, et al.
Blood|July 15, 1993
Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangementsF Lo Coco, P G Pelicci, F D'Adamo, et al.
Pageof 63